Delcath Systems Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Delcath Systems de 61.3% y 41.5% respectivamente, mientras que el BPA crecerá en un 65.9% al año.

Información clave

61.3%

Tasa de crecimiento de los beneficios

65.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	41.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	15 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:DCTH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	134	46	N/A	N/A	4
12/31/2025	70	-5	N/A	N/A	4
12/31/2024	26	-32	N/A	N/A	4
12/31/2023	2	-48	-31	-31	N/A
9/30/2023	2	-45	-30	-30	N/A
6/30/2023	3	-34	-27	-26	N/A
3/31/2023	3	-37	-23	-23	N/A
12/31/2022	3	-37	-25	-25	N/A
9/30/2022	4	-33	-24	-24	N/A
6/30/2022	4	-32	-24	-23	N/A
3/31/2022	4	-28	-25	-24	N/A
12/31/2021	4	-26	-23	-23	N/A
9/30/2021	2	-27	-22	-22	N/A
6/30/2021	2	-25	-22	-21	N/A
3/31/2021	2	-23	-23	-22	N/A
12/31/2020	2	-24	-24	-23	N/A
9/30/2020	2	-5	-24	-23	N/A
6/30/2020	2	-7	-31	-31	N/A
3/31/2020	2	-9	-26	-26	N/A
12/31/2019	2	-9	-24	-24	N/A
9/30/2019	2	-32	-20	-20	N/A
6/30/2019	3	-34	-11	-11	N/A
3/31/2019	3	-34	-11	-11	N/A
12/31/2018	3	-19	-15	-15	N/A
9/30/2018	3	-28	-17	-17	N/A
6/30/2018	3	-32	-17	-17	N/A
3/31/2018	3	-27	-18	-18	N/A
12/31/2017	3	-46	-16	-15	N/A
9/30/2017	3	-34	N/A	-15	N/A
6/30/2017	2	-23	N/A	-15	N/A
3/31/2017	2	-27	N/A	-14	N/A
12/31/2016	2	-18	N/A	-14	N/A
9/30/2016	2	-15	N/A	-15	N/A
6/30/2016	2	-16	N/A	-14	N/A
3/31/2016	2	-13	N/A	-16	N/A
12/31/2015	2	-15	N/A	-16	N/A
9/30/2015	2	-13	N/A	-15	N/A
6/30/2015	1	-15	N/A	-16	N/A
3/31/2015	1	-16	N/A	-15	N/A
12/31/2014	1	-17	N/A	-16	N/A
9/30/2014	1	-19	N/A	-18	N/A
6/30/2014	1	-22	N/A	-21	N/A
3/31/2014	1	-23	N/A	-28	N/A
12/31/2013	1	-30	N/A	-34	N/A
9/30/2013	1	-36	N/A	-38	N/A
6/30/2013	1	-41	N/A	-44	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que DCTH sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que DCTH sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que DCTH sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (41.5% al año) de DCTH crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (41.5% al año) de DCTH crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de DCTH se prevé que sea elevada dentro de 3 años.

Delcath Systems Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2026

No longer forecast to breakeven

Consensus revenue estimates fall by 34%

Consensus revenue estimates fall by 18%

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

Recent updates

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

Delcath Systems to raise $5M in stock and warrants offering

Delcath Systems: Revisiting A $5 Lottery Ticket

Price target decreased to US$21.20

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Price target decreased to US$22.00

Delcath Systems, Inc., Annual General Meeting, May 04, 2022

Consensus forecasts updated

Is Delcath Systems (NASDAQ:DCTH) Weighed On By Its Debt Load?

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT

Delcath Systems, Inc. Appoints Anthony Dias as its New Vice President of Finance

Delcath Systems, Inc. Announces Result of Single Center Study on Delcath’s CHEMOSAT Hepatic Delivery System Published in Melanoma Research

CEO & Director recently bought US$200k worth of stock

Price target increased to US$23.50

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.96 loss per share (vs US$1.91 loss in 2Q 2020)

Delcath Systems, Inc. announced that it expects to receive $20 million in funding from Avenue Capital Group

Diving Into Delcath Systems

CEO & Director recently bought US$149k worth of stock